Posts by Brian V. Nahed, MD, MSc
-
Cadaver-free Simulation Model Feasible for Improving Residents' Craniotomy Skills
Faith C. Robertson, MD, MSc, Brian V. Nahed, MD, MSc, and colleagues demonstrated in a pilot study that a set curriculum with a synthetic model of a pterional approach helped neurosurgical residents improve their speed and technical skill scores through spaced repetition over a relatively short period, six weeks.
-
Direct Cortical Recordings Feasible for Monitoring Thalamocortical Tract During Craniotomy
Monitoring thalamocortical afferents via direct cortical recordings is feasible during brain tumor surgery, Massachusetts General Hospital researchers have demonstrated. Sometimes, changes in surgical management in response to somatosensory changes evoked potentials prevented worsening of preoperative sensory deficits.
-
Circulating Blood Counts Predict Response, Survival in Recurrent Glioblastoma Treated with Bevacizumab
Massachusetts General Hospital researchers are the first to report that changes in eosinophil, lymphocyte and platelet counts might serve as biomarkers of clinical outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.
-
Incidence of Malignant Brain and Spinal Tumors Varies Substantially by World Region
According to the first study of the global burden of malignant brain and spinal tumors, there is substantial variation between regions, with the greatest incidence estimated in Europe and North America and the lowest in Africa and Southeast Asia.
-
The Mass General Neurosurgery Mission
Researchers from the Department of Neurosurgery at Massachusetts General Hospital discuss their collaborative work in clinical and translational research.
-
How Liquid Biopsies Can Improve Brain Tumor Diagnoses
Researchers at Mass General have developed a blood-based assay called liquid biopsy. This non-invasive procedure allows physicians to monitor a patient's tumor during treatment.
-
Liquid Biopsies Hold Promise for Diagnosis and Monitoring of Gliomas
Liquid biopsies—genetic analysis of blood or CSF—may someday be feasible for diagnosing glioma, matching patients to the right mutation-based therapy and monitoring outcomes.
-
Time Constraints, Barriers to Access Limit Opioid Prescription Monitoring by Neurosurgeons
The first survey to examine neurosurgeons use of prescription drug monitoring programs (PDMPs) suggests that misunderstandings and barriers to access are limiting the efficacy of these databases.
-
How Microfluidics Could Improve Neurosurgery
A team at Mass General are studying how the field of microfluidics could improve neurosurgical patient care, particularly in patients with brain tumors.
-
How Liquid Biopsy Could Improve Brain Tumor Treatment and Diagnoses
Mass General doctors are developing a liquid biopsy for brain tumors to reduce the need for invasive tissue biopsies.
Biography
Dr. Brian Nahed is a neurosurgeon specializing in brain tumors (glioblastoma, gliomas (low grade and high grade), metastatic brain tumors, and meningiomas) as well as Spinal Disorders. Dr. Nahed specializes in brain tumors of the eloquent cortex (language and motor areas of the brain) which require awake surgery, language and motor mapping, and subcortical stimulation.
Born in New York, Dr. Nahed attended UCLA where he majored in Neuroscience, graduating Phi Beta Kappa and with the department's Highest Honors. He attended the Yale School of Medicine where he was awarded the Doris Duke Clinical Research Fellowship and graduated with honors. Dr. Nahed completed his internship and neurosurgery residency at Mass General; where Dr. Nahed also completed a postdoctoral fellowship with Drs. Daniel Haber and Shyamala Maheswaran in the Mass General Cancer Center.
Dr. Brian Nahed was recruited to the MGH Department of Neurosurgery and Brain Tumor Center in 2011. As an Associate Professor at Harvard Medical School, Dr. Brian Nahed's research focuses on developing the first blood based test to diagnose and monitor brain tumors. In collaboration with Drs. Haber, Maheswaran, and Stott, Dr. Nahed recently published the first evidence of circulating tumor cells in the blood of patients with glioma. Dr. Nahed is actively enrolling patients into his translational clinical research study.
Dr. Brian Nahed serves as the Associate Director of the MGH Neurosurgery Residency Program. He serves on the Executive Committee of the Congress of Neurological Surgeons and the CNS/AANS section on Tumors. He is an active member of the American Association of Neurological Surgeons and Council State Neurological Societies. Dr. Nahed is focused on education and socioeconomic issues in neurosurgery. He also serves as a neurotrauma consultant for the National Football League (NFL).
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.